A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)
Condition: Healthy Volunteers
Intervention: TAK-653; Placebo; Ketamine
Intervention description: TAK-653 tablets.; TAK-653 placebo-matching tablets.; Ketamine intravenous infusion.
Intervention MeSH terms: Ketamine
Phase: Phase 1
Study type: Interventional
Primary purpose: Other
Allocation: Randomized
Intervention model: Crossover Assignment
Intervention model description: The study is a randomized, crossover 6 sequence study in Treatment Periods 1, 2, and 3.
Masking: Double (Participant, Investigator)
Masking description: The study is double blind in Treatment Periods 1, 2, and 3 and open-label in Treatment Period 4.
Enrollment: 24.0
Sex: All
Minimum age: 18 Years
Maximum age: 55 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Drug Therapy

Summary:

      The primary purpose of this study is to determine whether TAK-653, in comparison to placebo,
      increases CNS excitability, assessed with TMS-evoked motor-evoked potential (MEP) in healthy
      participants.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Must be judged to be in good health by the investigator, based on clinical evaluations
             including laboratory safety tests, medical history, physical examination, 12-lead
             electrocardiogram (ECG), and vital sign measurements performed at the screening visit
             and before the first dose of study drug.

          2. Must be male or female (of nonchildbearing potential) aged 18 to 55 years, inclusive,
             at the screening visit.

          3. Must have a body mass index (BMI) greater than or equal to (>=) 18.5 and less than or
             equal to (<=) 30.0 kilogram per square meter (kg/m^2) at the screening visit.

        Exclusion Criteria:

          1. Has a positive alcohol or drug screen.

          2. Had major surgery or donated or lost 1 unit of blood (approximately 500 milliliter
             [mL]) within 4 weeks before the screening visit.

          3. Has a history of alcohol consumption exceeding 2 standard drinks per day on average (1
             glass is approximately equivalent to the following: beer [354 mL/12 ounce (oz)], wine
             [118 mL/4 oz], or distilled spirits [29.5 mL/1 oz] per day).

          4. Who regularly smoke more than 5 cigarettes daily or equivalent and unable or unwilling
             not to smoke during the in-house period.

          5. Consumes excessive amounts, defined as greater than 6 servings (1 serving is
             approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks,
             or other caffeinated beverages per day.

          6. Has a previous or current clinically significant psychiatric disorder according to
             Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5)
             including substance use disorder.

          7. Has a history of intracranial mass lesion, hydrocephalus and/or head injury or trauma.

          8. Has metal objects in brain or skull.

          9. Has a cochlear implant or deep brain stimulation device.

         10. Has a history of epilepsy, seizures, or convulsions.

         11. Has a family history of epilepsy, seizures, or convulsions.

         12. Has abnormal sleeping patterns (example, working night shifts)

         13. Has an rMT of more than 75% of the maximum stimulator output, measured using
             TMS-electromyogram (EMG) during screening.